5 results on '"Beavers, Craig J."'
Search Results
2. Optimizing anticoagulation for patients receiving Impella support.
- Author
-
Beavers, Craig J., DiDomenico, Robert J., Dunn, Steven P., Cox, Jenna, To, Long, Weeks, Phillip, Trujillo, Toby C., and Jennings, Douglas L.
- Subjects
- *
HEPARIN , *ARTIFICIAL blood circulation , *ANTICOAGULANTS , *EXTRACORPOREAL membrane oxygenation - Abstract
Anticoagulation of patients treated with the Impella percutaneous mechanical circulatory support (MCS) devices is complex and lacks consistency across centers, potentially increasing the risk of complications. In order to optimize safety and efficacy, an expert committee synthesized all available evidence evaluating anticoagulation for patients receiving Impella support in order to provide consensus recommendations for the management of anticoagulation with these devices. The evidence synthesis led to the creation of 42 recommendations to improve anticoagulation management related to the use of the Impella devices. Recommendations address purge solution management, intravenous anticoagulation, monitoring, evaluation and management of heparin‐induced thrombocytopenia (HIT), and management during combination MCS support. The use of a heparinized, dextrose‐containing purge solution is critical for optimal device function, and a bicarbonate‐based purge solution may be an alternative in certain situations. Likewise, intravenous (ie, systemic) anticoagulation with heparin is often necessary, although evidence supporting the optimal assay and target range for monitoring the level of anticoagulation is generally lacking. Patients treated with an Impella MCS device may develop HIT, which is more difficult to evaluate and treat in this setting. Lastly, the use of Impella with extracorporeal membrane oxygenation or for biventricular support creates additional anticoagulation challenges. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. Distinguishing Anemia and Iron Deficiency of Heart Failure: Signal for Severity of Disease or Unmet Therapeutic Need?
- Author
-
Beavers, Craig J., Alburikan, Khalid A., Rodgers, Jo E., Dunn, Steven P., and Reed, Brent N.
- Subjects
- *
HEART failure , *IRON deficiency , *ANEMIA , *BLOOD transfusion , *INFLAMMATION - Abstract
Despite advances in the management of heart failure ( HF), quality of life and other outcomes remain suboptimal for many patients. Anemia and iron deficiency are comorbidities associated with adverse outcomes, although their pathophysiology in the setting of HF is not entirely understood. Anemia and iron deficiency may exist independently and may be a consequence of the systemic inflammatory state characterized by chronic HF. However, it is unclear whether serum hemoglobin concentrations and other hematologic parameters serve as markers for the severity of disease or represent novel therapeutic targets. Research in this area has focused primarily on therapies known to be effective for these conditions in other chronic disease states with similar pathophysiologic features (e.g., end-stage renal disease). Despite its many practical advantages, minimal evidence exists to support the use of oral iron supplementation in this setting. In contrast, intravenous iron has been the subject of several recent investigations, demonstrating improvements in both surrogate and clinical end points, although benefits seem to be the most substantial in patients with concomitant anemia. Erythropoietin-stimulating agents demonstrated early promise in retrospective analyses and small prospective trials, but their benefit was outweighed by a lack of improvement in clinical outcomes and an excess number of thromboembolic events in the largest trial of patients with anemia and HF to date. For acute symptomatic anemia, blood transfusion may be considered, although few trials have included patients with HF, and caution must be exerted in those who are hemodynamically unstable. Based on the currently available evidence, treatment of iron deficiency appears to confer benefit in patients with HF, whereas strategies aimed at improving hemoglobin alone do not. Included is a review of the pathophysiology of these conditions in the setting of HF, clinical trials evaluating pharmacologic therapy, and recommendations for management. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
4. Key Articles and Guidelines in the Management of Acute Coronary Syndrome and in Percutaneous Coronary Intervention: 2012 Update.
- Author
-
Dobesh, Paul P., Beavers, Craig J., Herring, Holly R., Spinler, Sarah A., Stacy, Zachary A., and Trujillo, Toby C.
- Subjects
- *
ACUTE coronary syndrome , *CARDIOVASCULAR disease treatment , *PATIENT management , *DRUG therapy , *PHARMACOGENOMICS , *CLOPIDOGREL , *CORONARY disease - Abstract
More than 1 million people in the United States experience an acute coronary syndrome ( ACS) every year, and almost 600,000 undergo percutaneous coronary intervention ( PCI) for treatment of cardiovascular disease. There is a large amount of evidence-based literature to guide appropriate management of these patients. There have been a number of advances in the treatment of these patients over the last several years. Due to the large amount of rapidly available literature concerning the care of patients with ACS or undergoing PCI, clinicians can often find it difficult to keep up with the information needed for optimizing care of these patients. Therefore, we provide the second update to the first compiled bibliography of key articles and guidelines relative to patients with ACS published in Pharmacotherapy in 2004. The initial update was published in Pharmacotherapy in 2007 and also included bibliographies concerning management of patients undergoing PCI. A number of guidelines and practice-changing literature have been published since the update in 2007. Specific areas included in this review are updated summaries of clinical practice guidelines and clinical trials of anticoagulants, antiplatelets, platelet aggregation testing, pharmacogenomics testing in patients taking clopidogrel, clopidogrel loading dose comparisons, clopidogrel and proton pump inhibitor drug interactions, the impact of bleeding in ACS, and statins. As with previous versions of this document, we hope that this compilation will serve as a resource for pharmacists, physicians, nurses, residents, and students responsible for the care of patients with coronary heart disease. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
5. Effective medications can work only in patients who take them: Implications for post‐acute heart failure care.
- Author
-
Cotter, Gad, Davison, Beth A., Adams, Kirkwood F., Ambrosy, Andrew P., Atabaeva, Lina, Beavers, Craig J., Bhatt, Ankeet S., Givertz, Michael M., Grodin, Justin L., Lala, Anuradha, Novosadov, Mikhail, Sokos, George G., Takagi, Koji, Teerlink, John R., and Bhatt, Deepak L.
- Subjects
- *
HEART failure , *PATIENTS' attitudes , *DRUGS , *MEDICAL personnel , *PATIENT compliance , *QUALITY of life , *CLINICAL trials monitoring - Abstract
Acute heart failure (AHF) is a common cause of hospitalization, particularly among older individuals, and has high mortality and readmission rates. Adherence to guideline-directed medical therapy (GDMT) is crucial for improving outcomes in heart failure (HF) patients, as non-adherence can lead to exacerbations and adverse outcomes. However, studies have shown that medication non-adherence rates among HF patients can be as high as 70%. Various factors contribute to non-adherence, including patient circumstances, treatment-related factors, and healthcare system and payer factors. Adherence interventions, such as patient education, medication regimen management, and reminders, have been shown to improve medication adherence and reduce mortality and hospital readmissions in HF patients. Improving adherence to GDMT is essential for improving AHF outcomes, and further research is needed to identify effective approaches to enhance medication adherence. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.